Optimizing Patient Outcomes in Pancreatic Cancer With Al B. Benson, MD, FACP, FASCO

With 5-year survival rates of only 37% for local disease, 12% for regional disease, and 3% for distant disease, pancreatic cancer is one of the most aggressive forms of cancer and one of the most challenging to treat. Despite the development of novel treatment approaches, therapeutic options remain limited. In this episode of Oncology Data Advisor, Al B. Benson, MD, Professor of Medicine at Northwestern University’s Feinberg School of Medicine and Associate Director for Cooperative Groups at Northwestern’s Robert H. Lurie Comprehensive Cancer Center, joins i3 Health for a discussion that covers recent developments in genomic testing and targeted therapies, supportive care measures that can optimize quality of life, and strategies that members of the cancer care team can utilize to improve the outcomes of their patients with pancreatic cancer.

TARGET AUDIENCE

Oncologists, gastroenterologists, oncology advanced practitioners, and other health care professionals involved in the treatment of patients with pancreatic cancer.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

Identify the role that biomarkers can play in predicting therapeutic efficacy and developing tailored approaches to treatment
Develop effective multidisciplinary approaches that can be used to enhance pancreatic cancer treatment and supportive care